Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IST + avatrombopag in elderly severe aplastic anemia (Phase 2, single-arm, China)
ChiCTR2200061174Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avatrombopag in aplastic anemia, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Complete response rate at 12 weeks. Started Jun 2022; status: recruiting.
02
Drugs
avatrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on ChiCTR2200061174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061174.